All In Biotech

Drug Trial Radar · NCT01932437

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers

Last checked: Nov 20, 2026Latest source record: May 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Jul 26, 2013

Primary completion

Jul 3, 2014

Study completion Jul 3, 2014

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers

Conditions

  • Inhalational Anthrax

Interventions

  • ETI-204Biological

    monoclonal antibody

  • PlaceboOther

    Placebo for ETI-204

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Adverse EventsTime frame: Up to 71 (+/- 4) days or for 30 additional days after the final study visit for subjects with ongoing adverse events at the final scheduled study visit, for each group.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.